320 related articles for article (PubMed ID: 20172545)
21. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
Hoffmann D; Bayer W; Wildner O
Int J Mol Med; 2007 Nov; 20(5):673-81. PubMed ID: 17912460
[TBL] [Abstract][Full Text] [Related]
23. The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis.
Brown CW; Stephenson KB; Hanson S; Kucharczyk M; Duncan R; Bell JC; Lichty BD
J Virol; 2009 Jan; 83(2):552-61. PubMed ID: 18971262
[TBL] [Abstract][Full Text] [Related]
24. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
Shinozaki K; Ebert O; Woo SL
Hepatology; 2005 Jan; 41(1):196-203. PubMed ID: 15619242
[TBL] [Abstract][Full Text] [Related]
25. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
26. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL
Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
28. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
29. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
30. Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model.
Duntsch CD; Zhou Q; Jayakar HR; Weimar JD; Robertson JH; Pfeffer LM; Wang L; Xiang Z; Whitt MA
J Neurosurg; 2004 Jun; 100(6):1049-59. PubMed ID: 15200120
[TBL] [Abstract][Full Text] [Related]
31. Recombinant replication-restricted VSV as an expression vector for murine cytokines.
Miller MA; Lavine CL; Klas SD; Pfeffer LM; Whitt MA
Protein Expr Purif; 2004 Jan; 33(1):92-103. PubMed ID: 14680966
[TBL] [Abstract][Full Text] [Related]
32. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
34. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.
Kahn JS; Schnell MJ; Buonocore L; Rose JK
Virology; 1999 Feb; 254(1):81-91. PubMed ID: 9927576
[TBL] [Abstract][Full Text] [Related]
35. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
Fredericksen BL; Whitt MA
Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
[TBL] [Abstract][Full Text] [Related]
36. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer.
Ebert O; Shinozaki K; Kournioti C; Park MS; García-Sastre A; Woo SL
Cancer Res; 2004 May; 64(9):3265-70. PubMed ID: 15126368
[TBL] [Abstract][Full Text] [Related]
37. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
[TBL] [Abstract][Full Text] [Related]
39. Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles.
Dalton KP; Rose JK
Virology; 2001 Jan; 279(2):414-21. PubMed ID: 11162797
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
